Ambisome amphotericin

Liposomes are lipid-based vesicles useful in delivering conventional as well as macromolecular therapeutic agents (35). The commercially available liposomal formulations include Doxil (doxorubicin) and Ambisome (amphotericin B), which are available for the treatment of tumors and fungal infections, respectively. Egg yolk and soy lecithins that are mainly composed of phospholipids (< 95%) are commonly used as raw materials for liposome preparation. Of the two, soy lecithins are generally preferred for reasons of... [Pg.386]

Liposome AmBisome Amphotericin B Parenteral NeXstar Pharmaceuticals... [Pg.580]

Currently, toxic effects of AmB have been largely ameliorated with the advent of lipid formulations, in these formulations, deoxycholate has been replaced by other Upids that mask AmB from susceptible tissues, thus reducing toxicity and facilitating its preferential uptake by reticuloendothelial cells. Thus, this drug delivery results in increasing efficacy and reduced toxicity. Three Upid-associated formulations of amphotericin are commercially available Uposomal amphotericin B (AmBisome), amphotericin B lipid complex (Abelcet), and amphotericin B colloidal dispersimi (Amphocil). These compoimds have been considered between the most striking advances in Leishmania therapy [52],... [Pg.4435]

Liposomal amphotericin B (AmBisome) may be more appropriate for disseminated disease. [Pg.427]

Lipid-associated formulations of amphotericin B, liposomal amphotericin B (AmBisome) and amphotericin B lipid complex (Abelcet) have been approved for use in proven cases of candidiasis however, patients with invasive candidiasis have also been treated successfully with amphotericin B colloid dispersion (Amphotec or Amphocil). The lipid-associated formulations are less toxic but as effective as amphotericin B deoxycholate. [Pg.435]

Solid-organ transplantation Liver transplantation Micafungin 50 mg (1 mg/kg in patients under 50 kg) IV daily Patients with two or more key risk factor Amphotericin B IV 10-20 mg daily or Liposomal amphotericin B (AmBisome) 1 mg/kg/day or flucona-... [Pg.436]

Liposomai amphotericin B (AmBisome) - The recommended dose is 3 to 5 mg/kg/day prepared as a 1 to 2 mg/mL infusion delivered initially over 120 minutes infusion time may be reduced to 60 minutes if well tolerated or increased if patient experiences discomfort. Lower infusion concentrations of... [Pg.1665]

Liposomal amphotericin B (AmBisome) - Administer 3 mg/kg/day on days 1 through 5, 14 and 21 to immunocompetent patients a repeat course of therapy may be useful if parasitic clearance is not achieved. Administer 4 mg/kg/day on days 1 through 5, 10, 17, 24, 31, and 38 to immunosuppressed patients seek expert advice regarding further therapy if parasitic clearance is not achieved. [Pg.1666]

Amphotericin B (Amphocin) Amphotericin B Cholesteryl (Amphotec) Amphotericin B Lipid Complex (Abelcet) Amphotericin B Liposomal (AmBisome) Anidulafungin (Eraxis)... [Pg.36]

Berman JD. Editorial response U. S. Food and Drug Administration approval of AmBisome (Liposomal Amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999 28 49-51. [Pg.619]

Ambisome , Daunoxome , liposomal amphotericin B and daunorubicin citrate injection. Liposomal lurtotecan in phase I clinical trials. Gilead Sciences Inc., Foster City, CA. [Pg.371]

Adler-Moore, J. P. and Prof tt, R. T. (1993). Development, characterization, ef cacy, and mode of action of AmBiSome, a unilamellar liposomal formulation of Amphotericin BLiposome Res., 3, 429-450. [Pg.409]

Several newer forms of amphotericin B (Abelcet, AmBisome, Amphotec) have also been developed. These drugs are encapsulated in small lipid spheres (liposomes) and then injected slowly by intravenous infusion.26,57 The lipid-based preparations appear to deliver higher doses of amphotericin B to the site of... [Pg.547]

S. D. Allen, K. N. Sorensen, M. J. Nejdi, C. Durrant, and R. T. Proffit, Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis,./. Antimicrob. Chemother. 34 1001... [Pg.88]

A commercial product based on conventional liposomes has been introduced for the parenteral delivery of the anti-fungal drug, amphotericin B, which is poorly tolerated in conventional formulations. AmBisome, a liposomal formulation of amphotericin B, comprises SUV of diameter 50-100 ran. Two other lipid-based formulations of amphotericin B have also recently been commercially introduced ... [Pg.121]

Daunorabicin (DaunoXome, Gilead Sciences, Inc.) Doxorubicin (Doxil/Caelyx, Ortho Biotech ProductsLP/Sequus Pharmaceuticals) Amphotericin B (Ambisome/Abelcet, Fujisawa Healthcare, Wyeth Pharmaceuticals) Doxorubicin (Myocet/Evacet, Sopherion/ Liposome Company) Hepatitis A virus envelope proteins (Epaxal, Berna Biotech) Influenza virus (Inflexal V, Berna Biotech) Verteporfin (Visudyne, Novartis Ophthalmics) Kaposi s sarcoma Kaposi s sarcoma Fungal infections in immunocompromised patients Metastatic breast cancer Hepatitis A Influenza Age-related macular degeneration... [Pg.483]

Amphotericin B AmBisome (lyophihzed product) HSPC, cholesterol, DSPG, a-tocopherol, sucrose, disodium succinate Fungal infections Gilead Sciences... [Pg.1263]

Amphotericin B Abelcet (ABLC) [injectable 5 mg/ml, Upid complex],Ambisome (L-AMB) [injectable 50 mg/vial,liposomal].Amphocin (injectable 50 mg/vial, nonlipid),Amphotec (ABCD) [injectable 50 mg/vial, 100 mg/vial, colloidal dispersion], Fungizone [injectable 50 mg/vial, nonlipid], generic also available. [Pg.209]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...